•  
  •  
image-724031-Janssen_logo.png
image-724110-Early_logo.jpg
B60-US00063

What follows is a brief summary of the Janssen EARLY trial for individuals with "pre-clinical" aymptomatic Alzheimer's pathology. 

  • Drug administration -- daily oral

  • Age range -- 60-85

  • CDR range -- global score 0, only

  • Study Duration -- 4.5 years

  • Target population -- amyloid PET or CSF positive asymptomatic individuals

  • Mechanism of action -- blocks formation of active beta amyloid protein (BACE inhibition)

  • Randomization split -- 50:50 active : placebo

  • Type(s) of imaging -- brain MRI, amyloid PET, tau PET


For more details on this specific trial, visit:


                                                                                      ClinicalTrials.gov

A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060